Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Creative Medical Technology Holdings, Inc. (CELZ) AI Forecast

Our AI detected a significant signal for Creative Medical Technology Holdings, Inc.. Create a free account to see the exact price target.

Free account • 30-day free trial

$CELZ Bullish Signal Full forecast available

Creative Medical Technology Holdings, Inc. (CELZ) Stock Forecast 2025


Creative Medical Technology Holdings, Inc. (CELZ) AI Stock Price Forecast & Investment Analysis

Creative Medical Technology Holdings, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Creative Medical Technology Holdings, Inc. (CELZ) - Comprehensive Stock Analysis & Investment Research

Deep dive into Creative Medical Technology Holdings, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on April 2, 2026, 7:26 a.m. (UTC)

Creative Medical Technology Holdings, Inc. Investment Summary

When evaluating whether Creative Medical Technology Holdings, Inc. (CELZ) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Creative Medical Technology Holdings, Inc. (CELZ) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. The company employs approximately 4 people. With a market capitalization of $7 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Creative Medical Technology Holdings, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Creative Medical Technology Holdings, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Creative Medical Technology Holdings, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Creative Medical Technology Holdings, Inc.

Sign Up Free
Corporate Identity

Creative Medical Technology Holdings, Inc. (Stock Symbol: CELZ) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Creative Medical Technology Holdings, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Creative Medical Technology Holdings, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Creative Medical Technology Holdings, Inc....

Unlock Full Company Profile

Get complete details about Creative Medical Technology Holdings, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Creative Medical Technology Holdings, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Creative Medical Technology Holdings, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Creative Medical Technology Holdings, Inc....

Unlock Financial Analysis

Get complete financial metrics for Creative Medical Technology Holdings, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Creative Medical Technology Holdings, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Creative Medical Technology Holdings, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Creative Medical Technology Holdings, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-3 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Margin & Pricing Power Analysis

The company maintains a 60.0% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.

Operating margin of -33117.5% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Asset Utilization Efficiency

Asset turnover ratio of 0.02x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 24.29 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Creative Medical Technology Holdings, Inc. (CELZ) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Creative Medical Technology Holdings, Inc. stock analysis.

Deep dive into Creative Medical Technology Holdings, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Creative Medical Technology Holdings, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Creative Medical Technology Holdings, Inc.: With a P/E ratio of -3.38, the market sees the stock as potentially undervalued.

P/E Ratio -3.38x
P/B Ratio 0.98x
Market Cap $7M
EPS $-0.18
Book Value/Share $2.03
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Creative Medical Technology Holdings, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Creative Medical Technology Holdings, Inc.: An ROE of -305.3% indicates room for improvement in shareholder value creation.

ROE -305.3%
ROA -185.4%
ROIC -182.9%
Gross Margin 60.0%
Operating Margin -33117.5%
Net Margin -31282.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Creative Medical Technology Holdings, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Creative Medical Technology Holdings, Inc.: A current ratio of 24.29 indicates strong liquidity.

Current Ratio 24.29x
Quick Ratio 24.08x
Financial Leverage 1.04x
Interest Coverage -1.5x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Creative Medical Technology Holdings, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Creative Medical Technology Holdings, Inc.: Free cash flow of $-3M indicates cash challenges that need attention.

Operating Cash Flow -$3M
Free Cash Flow -$3M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Creative Medical Technology Holdings, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Creative Medical Technology Holdings, Inc.: An asset turnover of 0.02x suggests room for improvement in asset utilization.

Asset Turnover 0.02x
Receivables Turnover 70.6x
Inventory Turnover 3.9x
Days Sales Outstanding 5 days
Days Inventory 94 days
Payables Period 2306 days
Cash Conversion Cycle -4147 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Creative Medical Technology Holdings, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Creative Medical Technology Holdings, Inc.:

Income Statement
R&D Expense $2M
Cost of Goods Sold $10K
Balance Sheet Highlights (% Of Assets)
Total Current Assets 95%
Cash & Short-term Investments 94%
Total Liabilities 4%
Short-term Debt 88%
Accounts Receivable 0%
Inventory 0%
Dividend & Shareholder Information
Shares Outstanding 4M
Growth Metrics (YoY)
EPS Growth -7.4%

Latest Creative Medical Technology Holdings, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Creative Medical Technology Holdings, Inc. (CELZ) stock price and investment outlook.

More news available

Sign up free to read all 7 news articles and stay updated on market developments.

Sign Up Free to Read More

Creative Medical Technology Holdings, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Creative Medical Technology Holdings, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $188M -1.9x 2.7x
Abpro Holdings, Inc. ABP ██% $310K x 0.0x
Abpro Holdings, Inc. ABPO ██% $460K x x
Arcellx, Inc. ACLX ██% $6.65B -74.1x 16.5x
Alpha Cognition Inc. ACOG ██% $135M x 2.2x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $2.17B 14.8x 4.6x
Adaptive Biotechnologies Corp ADPT ██% $2.23B -4.6x 10.2x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $120M 1047.3x 33.5x
Agentix Corp. AGTX ██% $2M x 249.3x
Aim Immunotech Inc. AIM ██% $2M -0.5x 0.9x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $284M -1.2x 9.3x
Aligos Therapeutics, Inc. ALGS ██% $49M -19.2x 0.9x
Allogene Therapeutics, Inc. ALLO ██% $593M -1.4x 2.0x
Alvotech ALVO ██% $1.13B x x
Amgen Inc AMGN ██% $190.18B 24.7x 22.0x
Apogee Therapeutics, Inc. APGE ██% $5.77B -20.5x 4.3x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $46.03B x x
Armata Pharmaceuticals, Inc. ARMP ██% $378M -1.0x 16.4x
Artiva Biotherapeutics, Inc. ARTV ██% $165M x 1.5x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $42M 1.3x 4.7x
Atyr Pharma Inc ATYR ██% $84M -3.6x 1.2x
Aura Biosciences, Inc. AURA ██% $427M -4.9x 3.1x
Autolus Therapeutics Plc AUTL ██% $365M x 2.1x
Anavex Life Sciences Corp. AVXL ██% $289M -17.3x 2.3x
Bioatla, Inc. BCAB ██% $11M -1.1x 23.3x
Biocardia, Inc. BCDA ██% $12M -0.6x 13.9x
Brainstorm Cell Therapeutics Inc. BCLI ██% $10M -4.9x 6.0x
Biocryst Pharmaceuticals Inc BCRX ██% $2.35B 8.9x 70.5x
Black Diamond Therapeutics, Inc. BDTX ██% $133M 6.0x 1.2x
Beam Therapeutics Inc. BEAM ██% $2.46B -12.6x 2.0x
Biogen Inc. BIIB ██% $26.98B 20.9x 1.5x
Biontech Se BNTX ██% $22.47B x x
Cabaletta Bio, Inc. CABA ██% $269M -1.6x 2.4x
Candel Therapeutics, Inc. CADL ██% $365M -4.6x 7.0x
C4 Therapeutics, Inc. CCCC ██% $262M -2.6x 1.0x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $7M -3.4x 1.0x
Cero Therapeutics Holdings, Inc. CERO ██% $650K x -196.2x
Cullinan Therapeutics, Inc. CGEM ██% $840M -4.1x 2.1x
Compugen Ltd CGEN ██% $208M 2.9x 2.0x
Cg Oncology, Inc. CGON ██% $5.39B x 7.2x
Cognition Therapeutics Inc CGTX ██% $79M -0.5x 2.3x
Coherus Oncology, Inc. CHRS ██% $261M 1.6x 4.3x
Calidi Biotherapeutics, Inc. CLDI ██% $2M -0.9x 0.6x
Cellectis S.A. CLLS ██% $340M x x
Compass Therapeutics, Inc. CMPX ██% $968M -4.8x 4.9x
Mosaic Immunoengineering Inc. CPMV ██% $5M x 20.9x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $110M -4.0x 2.4x
Cardiol Therapeutics Inc. CRDL ██% $156M x x
Curis Inc CRIS ██% $21M -0.3x 3.9x
Crispr Therapeutics Ag CRSP ██% $4.68B -12.1x 2.4x
Champions Oncology, Inc. CSBR ██% $82M 32.9x 19.2x
Cel Sci Corp CVM ██% $29M -0.9x 2.6x
Dbv Technologies S.A. DBVT ██% $1.14B -3.3x 6.8x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $395M -13.9x 0.8x
Denali Therapeutics Inc. DNLI ██% $3.07B -8.7x 3.0x
Precision Biosciences Inc DTIL ██% $137M -2.2x 1.5x
Dyadic International Inc DYAI ██% $31M -7.3x 25.0x
Editas Medicine, Inc. EDIT ██% $255M -0.8x 9.4x
Elutia Inc. ELUT ██% $45M 0.9x 1.6x
Engene Holdings Inc. ENGN ██% $453M 3.7x 1.6x
Entera Bio Ltd. ENTX ██% $53M 8.5x 4.0x
Viskase Holdings, Inc. ENZN ██% $4M x 10.3x
Estrella Immunopharma, Inc. ESLA ██% $45M -3.1x 289.4x
Evaxion A/S EVAX ██% $33M x x
Exelixis, Inc. EXEL ██% $11.56B 14.8x 5.4x
Exozymes Inc. EXOZ ██% $71M x 20.9x
Fate Therapeutics Inc FATE ██% $143M -1.3x 0.7x
4d Molecular Therapeutics, Inc. FDMT ██% $504M -3.0x 1.0x
Fennec Pharmaceuticals Inc. FENC ██% $219M 1758.3x 6.2x
Finch Therapeutics Group, Inc. FNCH ██% $15M 0.5x 1.1x
Futuretech Ii Acquisition Corp. FTII ██% $52M x -0.7x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $174.11B 20.5x 7.7x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.37B 59.5x 5.9x
Genenta Science S.P.A. GNTA ██% $16M x 1.3x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $340K x x
Greenland Mines Ltd GRML ██% $45M x 4.5x
Halozyme Therapeutics, Inc. HALO ██% $7.70B 24.3x 157.8x
Humacyte, Inc. HUMA ██% $131M -3.3x 42.3x
Immunitybio, Inc. IBRX ██% $7.22B -3.6x 57.4x
Inhibikase Therapeutics, Inc. IKT ██% $239M -1.0x 1.4x
Imagenebio, Inc. IMA ██% $56M x 0.4x
Immunocore Holdings Plc IMCR ██% $1.54B x 4.0x
Immatics N.V. IMTX ██% $1.34B x x
Immunovant, Inc. IMVT ██% $5.10B -14.5x 5.2x
In8bio, Inc. INAB ██% $14M x 0.5x
Inhibrx Biosciences, Inc. INBX ██% $873M -6.8x 109.2x
Mink Therapeutics, Inc. INKT ██% $45M -1.5x 6.7x
Inmune Bio, Inc. INMB ██% $33M -2.5x 1.4x
Intensity Therapeutics, Inc. INTS ██% $14M -2.2x 1.2x
Iovance Biotherapeutics, Inc. IOVA ██% $1.42B -4.5x 2.0x
Century Therapeutics, Inc. IPSC ██% $394M -0.7x 2.5x
Invivyd, Inc. IVVD ██% $375M -0.4x 1.6x
Jasper Therapeutics, Inc. JSPR ██% $22M -3.2x 5.4x
Kalaris Therapeutics, Inc. KLRS ██% $136M x 1.7x
Klotho Neurosciences, Inc. KLTO ██% $56M x 5.7x
Kodiak Sciences Inc. KOD ██% $2.64B -2.5x 16.8x
Krystal Biotech, Inc. KRYS ██% $7.56B 36.9x 6.2x
Kymera Therapeutics, Inc. KYMR ██% $6.91B -17.8x 4.4x
Kyverna Therapeutics, Inc. KYTX ██% $530M x 2.3x
Ladrx Corp LADX ██% $20K x 0.1x
Lineage Cell Therapeutics, Inc. LCTX ██% $387M -4.7x 8.7x
Lenz Therapeutics, Inc. LENZ ██% $293M -6.7x 1.0x
Liminatus Pharma, Inc. LIMN ██% $7M x x
Leonabio, Inc. LONA ██% $94M x 3.4x
Lexeo Therapeutics, Inc. LXEO ██% $414M -0.4x 1.7x
Maze Therapeutics, Inc. MAZE ██% $1.43B x 4.0x
Mesoblast Ltd MESO ██% $2.07B x x
Meiragtx Holdings Plc MGTX ██% $737M -3.4x 201.5x
Metagenomi Therapeutics, Inc. MGX ██% $50M x 0.3x
Molecular Partners Ag MOLN ██% $162M x x
Moderna, Inc. MRNA ██% $19.71B -3.2x 2.3x
Neurocrine Biosciences Inc NBIX ██% $13.27B 27.7x 4.1x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $399M -3.9x 3.0x
Novavax Inc NVAX ██% $1.51B 3.4x 40.0x
Ocugen, Inc. OCGN ██% $547M -4.3x 154.7x
Outlook Therapeutics, Inc. OTLK ██% $22M -0.2x 2.1x
Palisade Bio, Inc. PALI ██% $291M -0.2x 2.3x
Passage Bio, Inc. PASG ██% $22M -0.6x 1.2x
Vaxcyte, Inc. PCVX ██% $7.62B -20.4x 2.8x
Biomx Inc. PHGE ██% $8M 1.5x 0.8x
Pluri Inc. PLUR ██% $34M -1.4x 352.9x
Protalix Biotherapeutics, Inc. PLX ██% $173M 41.2x 3.6x
Pharmacyte Biotech, Inc. PMCB ██% $8M 0.3x 0.2x
Prime Medicine, Inc. PRME ██% $617M -1.5x 5.1x
Prokidney Corp. PROK ██% $526M x 0.0x
Qiagen N.V. QGEN ██% $9.11B x 2.6x
Quince Therapeutics, Inc. QNCX ██% $5M -1.7x 5.1x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $602M -3.8x 2.9x
Repligen Corp RGEN ██% $6.61B 135.2x 3.1x
Regenxbio Inc. RGNX ██% $418M -1.8x 4.1x
Relay Therapeutics, Inc. RLAY ██% $1.84B -2.0x 3.2x
Revolution Medicines, Inc. RVMD ██% $19.08B -11.1x 11.7x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.58B -4.7x 1.4x
Sab Biotherapeutics, Inc. SABS ██% $273M 20.6x 1.8x
Sana Biotechnology, Inc. SANA ██% $740M -2.1x 4.6x
Scilex Holding Co SCLX ██% $47M -0.4x 4.5x
Scinai Immunotherapeutics Ltd. SCNI ██% $2M -287.8x 0.3x
Sangamo Therapeutics, Inc SGMO ██% $82M -1.6x 13.1x
Solid Biosciences Inc. SLDB ██% $715M -0.9x 4.0x
Silexion Therapeutics Corp SLXN ██% $4M x 1.5x
Senti Biosciences, Inc. SNTI ██% $24M -1.1x 4.3x
Scholar Rock Holding Corp SRRK ██% $5.22B -18.5x 21.3x
Surrozen, Inc./De SRZN ██% $343M -0.5x 7.3x
Sutro Biopharma, Inc. STRO ██% $356M -1.0x 8.0x
Protara Therapeutics, Inc. TARA ██% $278M -2.1x 1.4x
Tarsus Pharmaceuticals, Inc. TARS ██% $2.87B -12.4x 8.4x
Tc Biopharm (Holdings) Plc TCBPY ██% $10K x 0.0x
Tscan Therapeutics, Inc. TCRX ██% $57M -4.6x 0.5x
Bio-Techne Corp TECH ██% $8.20B 101.1x 4.1x
Tectonic Therapeutic, Inc. TECX ██% $587M -8.9x 2.3x
Instil Bio, Inc. TIL ██% $56M -1.1x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $159M -2.5x 1.3x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.26B -3.0x 5.1x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $17M x 1274.2x
Twist Bioscience Corp TWST ██% $2.85B -12.6x 6.3x
Voyager Acquisition Corp./Cayman Islands VACH ██% $372M 41.3x 0.0x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $548M x x
Vericel Corp VCEL ██% $1.61B 97.7x 4.6x
Vir Biotechnology, Inc. VIR ██% $1.47B -2.0x 1.8x
Vivosim Labs, Inc. VIVS ██% $4M x 1.0x
Vor Biopharma Inc. VOR ██% $738M -0.6x 11.2x
Vaxart, Inc. VXRT ██% $146M 8.9x 1.7x
Voyager Therapeutics, Inc. VYGR ██% $238M 570.6x 1.2x
Windtree Therapeutics Inc /De/ WINT ██% $320K -0.4x 0.1x
X4 Pharmaceuticals, Inc XFOR ██% $375M 6.4x 2.0x
Zeo Scientifix, Inc. ZEOX ██% $17M x 25.0x
Zivo Bioscience, Inc. ZIVO ██% $26M -31.3x 17.0x
Zura Bio Ltd ZURA ██% $565M x 5.6x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Creative Medical Technology Holdings, Inc. Stock Forecast

How accurate are Creative Medical Technology Holdings, Inc. stock predictions?

Our AI model shows a 21% Spearman correlation coefficient for CELZ predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Creative Medical Technology Holdings, Inc. stock price forecasts?

Our analysis considers Creative Medical Technology Holdings, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Creative Medical Technology Holdings, Inc. a good investment in 2025?

Based on our AI analysis, Creative Medical Technology Holdings, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Creative Medical Technology Holdings, Inc. forecasts updated?

Creative Medical Technology Holdings, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Creative Medical Technology Holdings, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...